title: Endotoxin- and interleukin-1-induced hypophagia are not affected by adrenergic, dopaminergic, histaminergic, or muscarinic antagonists.
abstract: Endotoxin (lipopolysaccharide, LPS) and interleukin-1 (IL-1) administration induce hypophagia in rodents. Both IL-1 and LPS are known to activate cerebral norepinephrine and serotonin metabolism, and IL-1 affects that of acetylcholine and histamine. Each of these neurotransmitters has been implicated in feeding behavior. Therefore, the ability of specific antagonists of the above neurotransmitter systems to counteract feeding responses to peripherally injected mIL-1beta and LPS was studied. Feeding was assessed in nondeprived mice by measuring the intake of sweetened milk in a 30-min period, as well as daily food pellet intake. LPS and mIL-1beta reliably reduced milk intake, and often reduced food pellet intake and body weight. Treatment of the mice with peripherally administered alpha-adrenergic (phentolamine or prazosin) or 3-adrenergic antagonists (propranolol), either alone or in combination, did not significantly alter the hypophagic responses to mIL-1beta or LPS. Mice in which cerebral norepinephrine was depleted with DSP-4 or 6-hydroxydopamine also displayed the usual hypophagia in response to mIL-1beta and LPS. The hypophagic responses to mIL-1beta and LPS were not affected by the histaminergic antagonists, pyrilamine (H1), cimetidine (H2), thioperamide (H3), or the histamine-depleting agent, alpha-fluoromethylhistidine, nor by the muscarinic cholinergic antagonist, scopolamine. The responses to mIL-l1 were also unaffected by the dopamine receptor antagonist, haloperidol, the opioid receptor antagonist, naloxone, and the NO synthase inhibitor, L-NAME. These results suggest that adrenergic, dopaminergic, histaminergic, cholinergic, opioid or nitric oxide systems are not essential for the hypophagia induced by IL-1, and that multiple redundant pathways may be involved in illness-related hypophagia.
authors.affiliation: Department of Pharmacology and Therapeutics, Louisiana State University Medical Center, Shreveport 71130-3932, USA.
authors.forename: A H
authors.initials: AH
authors.lastname: Swiergiel
authors.forename: T
authors.initials: T
authors.lastname: Burunda
authors.forename: B
authors.initials: B
authors.lastname: Patterson
authors.forename: A J
authors.initials: AJ
authors.lastname: Dunn
mesh_terms: D018674:Adrenergic Antagonists / Q000494:pharmacology; D000818:Animals; D001596:Benzylamines / Q000494:pharmacology; D001679:Biogenic Amines / Q000037:antagonists & inhibitors*; D018492:Dopamine Antagonists / Q000494:pharmacology; D004731:Endotoxins / Q000494:pharmacology*; D004926:Escherichia coli; D005247:Feeding Behavior / Q000187:drug effects*; D006633:Histamine Antagonists / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D051379:Mice; D018727:Muscarinic Antagonists / Q000494:pharmacology; D016627:Oxidopamine / Q000494:pharmacology; D013565:Sympatholytics / Q000494:pharmacology
chemical_list: D018674:Adrenergic Antagonists; D001596:Benzylamines; D001679:Biogenic Amines; D018492:Dopamine Antagonists; D004731:Endotoxins; D006633:Histamine Antagonists; D007375:Interleukin-1; D008070:Lipopolysaccharides; D018727:Muscarinic Antagonists; D013565:Sympatholytics; C044101:endotoxin, Escherichia coli; D016627:Oxidopamine; C012102:DSP 4